JP Morgan Chase
TRVI icon

JP Morgan Chase’s Trevi Therapeutics TRVI Stock Holding History

JP Morgan Chase’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$91.5K – 7788
2025
Q3 		$91.5K Hold
10,000
– – ﹤0.01% 5951
2025
Q2 		$54.7K Buy
+10,000
New +$62.2K ﹤0.01% 5892

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

JP Morgan Chase's TRVI Position: Q2 2026 in Review

JP Morgan Chase increased its Trevi Therapeutics (TRVI) stake by 3.7% in Q2 2026, buying an estimated $38.4K and bringing the position to 73,273 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4464.

JP Morgan Chase first reported a position in TRVI in Q2 2020 and has held it in 15 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • JP Morgan Chase held 73,273 shares of Trevi Therapeutics worth $1.37M as of Q2 2026.
  • JP Morgan Chase bought 2,642 Trevi Therapeutics shares in Q2 2026, an estimated $38.4K.
  • Trevi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4464 holding.
  • JP Morgan Chase first reported a position in Trevi Therapeutics in Q2 2020 and has held it in 15 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.